Barclays Issues Positive Forecast for Lumexa Imaging (NASDAQ:LMRI) Stock Price

Lumexa Imaging logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Barclays raised its price target on Lumexa Imaging from $13 to $17 and maintained an “overweight” rating, implying 13.17% upside from the stock’s current price.
  • Analyst sentiment is broadly positive: MarketBeat reports a consensus “Buy” rating and an average price target of $17.60, though one analyst rates the stock a sell.
  • Lumexa reported quarterly earnings of $0.26 per share, beating the $0.07 consensus estimate; revenue was $271.97 million.
  • Interested in Lumexa Imaging? Here are five stocks we like better.

Lumexa Imaging (NASDAQ:LMRI - Get Free Report) had its target price upped by investment analysts at Barclays from $13.00 to $17.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm presently has an "overweight" rating on the stock. Barclays's price objective suggests a potential upside of 13.17% from the company's current price.

Other equities research analysts have also recently issued reports about the stock. KeyCorp assumed coverage on shares of Lumexa Imaging in a research report on Thursday, September 24th. They issued an "overweight" rating and a $18.00 target price for the company. Raymond James Financial set a $19.00 target price on shares of Lumexa Imaging and gave the stock a "strong-buy" rating in a research note on Wednesday, November 11th. Weiss Ratings downgraded Lumexa Imaging from a "sell (d)" rating to a "sell (d-)" rating in a research report on Friday. Truist Financial initiated coverage on shares of Lumexa Imaging in a research note on Monday, October 5th. They set a "buy" rating and a $18.00 price target on the stock. Finally, Wall Street Zen raised Lumexa Imaging from a "hold" rating to a "buy" rating in a research report on Saturday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $17.60.

View Our Latest Stock Analysis on LMRI

Lumexa Imaging Price Performance

Shares of NASDAQ:LMRI opened at $15.02 on Tuesday. The company's 50 day moving average is $11.50 and its 200 day moving average is $11.09. The company has a market cap of $1.44 billion and a PE ratio of -27.81. Lumexa Imaging has a twelve month low of $6.45 and a twelve month high of $19.45. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 1.40.

Lumexa Imaging (NASDAQ:LMRI - Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported $0.26 EPS for the quarter, topping analysts' consensus estimates of $0.07 by $0.19. Lumexa Imaging had a negative return on equity of 2.93% and a negative net margin of 1.96%. The firm had revenue of $271.97 million for the quarter. On average, sell-side analysts forecast that Lumexa Imaging will post 0.22 EPS for the current year.

Institutional Trading of Lumexa Imaging

Institutional investors and hedge funds have recently made changes to their positions in the company. Jupiter Topco LLC acquired a new stake in shares of Lumexa Imaging in the second quarter worth $24,269,000. Brooklands Fund Management Ltd acquired a new stake in shares of Lumexa Imaging during the 3rd quarter valued at approximately $21,577,000. BlackRock Inc. acquired a new position in Lumexa Imaging in the second quarter valued at approximately $15,771,000. Brigade Capital Management LP bought a new position in shares of Lumexa Imaging during the second quarter worth about $7,511,000. Finally, First Eagle Investment Management LLC acquired a new stake in Lumexa Imaging in the 3rd quarter valued at approximately $4,753,000.

About Lumexa Imaging

(Get Free Report)

Lumexa Imaging operates outpatient diagnostic imaging centers that provide radiology services to patients, referring physicians and healthcare providers. Its services include imaging used to help diagnose and monitor a range of medical conditions. The company offers diagnostic procedures such as MRI, CT, PET/CT, mammography, ultrasound and X-ray through its imaging centers and affiliated radiology practices. Lumexa serves communities across the United States, providing an outpatient option for medical imaging outside of a hospital setting.

Further Reading

Analyst Recommendations for Lumexa Imaging (NASDAQ:LMRI)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Lumexa Imaging Right Now?

Before you consider Lumexa Imaging, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lumexa Imaging wasn't on the list.

While Lumexa Imaging currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines